Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy

Triple negative breast cancer (TNBC) is an aggressive disease with high relapse rates and few treatment options. Outlined in previous publications, we identified a series of potent, dual TTK/CLK2 inhibitors with strong efficacy in TNBC xenograft models. Pharmacokinetic properties and kinome selectiv...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2019-05, Vol.62 (9), p.4401-4410
Main Authors: Riggs, Jennifer R, Elsner, Jan, Cashion, Dan, Robinson, Dale, Tehrani, Lida, Nagy, Mark, Fultz, Kimberly E, Krishna Narla, Rama, Peng, Xiaohui, Tran, Tam, Kulkarni, Ashutosh, Bahmanyar, Sogole, Condroski, Kevin, Pagarigan, Barbra, Fenalti, Gustavo, LeBrun, Laurie, Leftheris, Katerina, Zhu, Dan, Boylan, John F
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple negative breast cancer (TNBC) is an aggressive disease with high relapse rates and few treatment options. Outlined in previous publications, we identified a series of potent, dual TTK/CLK2 inhibitors with strong efficacy in TNBC xenograft models. Pharmacokinetic properties and kinome selectivity were optimized, resulting in the identification of a new series of potent, selective, and orally bioavailable TTK inhibitors. We describe here the structure–activity relationship of the 2,4-disubstituted-7H-pyrrolo­[2,3-d]­pyrimidine series, leading to significant single agent efficacy in a TNBC xenograft model without body weight loss. The design effort evolving an iv-dosed TTK/CLK2 inhibitor to an orally bioavailable TTK inhibitor is described.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.8b01869